Trial reportThorax2005
Inhaled fluticasone in bronchiectasis: a 12 month study.
Trial report in Thorax, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bacteriology and Sputum and Systemic Inflammation in Steady-state, Acute Exacerbation and Recovery of Bronchiectasis
Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis With Airway Limitation: a Prospective Study
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Management of Adult Bronchiectasis: Consensus-Based Guidelines of the German Respiratory Society.Respiration; international review of thoracic diseases · 2026Guideline
- Inhaled corticosteroids for bronchiectasis.The Cochrane database of systematic reviews · 2018Pooled it
- Bronchiectasis.BMJ clinical evidence · 2008Pooled it
- Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis.International journal of clinical pharmacy · 2012Trial
- Eosinophilic and type 2 inflammation in bronchiectasis: from phenotype recognition toward endotype-informed therapy.Frontiers in medicine · 2026Review
- Bronchodilator response as an independent predictor of severity in bronchiectasis.Journal of thoracic disease · 2025Article
- Bronchodilators and inhaled corticosteroids use in major global bronchiectasis registries.Journal of thoracic disease · 2025Article
- Clinical outcomes of long-term inhaled combination therapies in patients with bronchiectasis and airflow obstruction.BMC pulmonary medicine · 2024Article
- Blood eosinophil percentage as a predictor of response to inhaled corticosteroid in bronchiectasis.The clinical respiratory journal · 2023Article
- Features of osteoporosis in male patients with bronchiectasis, a cross-sectional study.Journal of thoracic disease · 2023Article
- Insights into Personalised Medicine in Bronchiectasis.Journal of personalized medicine · 2023Review
- Review
- Is bronchiectasis really a disease?European respiratory review : an official journal of the European Respiratory Society · 2020Article
- Effect of short-term inhalation of warm saline atomised gas on patients with non-cystic fibrosis bronchiectasis.ERJ open research · 2020Article
- The Spectrum of Non-asthmatic Airway Diseases Contributing to Cough in the Adult.Current otorhinolaryngology reports · 2019Review
- Clinical Practice Guidelines for Diagnosis and Management of Cough-Chinese Thoracic Society (CTS) Asthma Consortium.Journal of thoracic disease · 2018Review
- Sputum purulence-associated microbial community compositions in adults with bronchiectasis.Journal of thoracic disease · 2018Article
- A pediatric disease to keep in mind: diagnostic tools and management of bronchiectasis in pediatric age.Italian journal of pediatrics · 2017Review
- Diagnosis and management of bronchiectasis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical efficacy of inhaled corticosteroid (ICS) treatment has not been evaluated in bronchiectasis, despite the presence of chronic airway inflammation.
methodsAfter three consecutive weekly visits, 86 patients were randomised to receive either fluticasone 500 mug twice daily (n = 43, 23F, mean (SD) age 57.7 (14.4) years) or matched placebo (n = 43, 34F, 59.2 (14.2) years) and reviewed regularly for 52 weeks in a double blind fashion.
results35 and 38 patients in the fluticasone and placebo groups completed the study. Significantly more patients on ICS than on placebo showed improvement in 24 hour sputum volume (OR 2.5, 95% CI 1.1 to 6.0, p = 0.03) but not in exacerbation frequency, forced expiratory volume in 1 second, forced vital capacity, or sputum purulence score. Significantly more patients with Pseudomonas aeruginosa infection receiving fluticasone showed improvement in 24 hour sputum volume (OR 13.5, 95% CI 1.8 to 100.2, p = 0.03) and exacerbation frequency (OR 13.3, 95% CI 1.8 to 100.2, p = 0.01) than those given placebo. Logistic regression models revealed a significantly better response in sputum volume with fluticasone treatment than with placebo among subgroups of patients with 24 hour sputum volume <30 ml (p = 0.04), exacerbation frequency </=2/year (p = 0.04), and sputum purulence score >5 (p = 0.03).
conclusionsICS treatment is beneficial to patients with bronchiectasis, particularly those with P. aerurginosa infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.